← Back to Search

Behavioral Intervention

Mind the Gap Intervention for Autism (MTG Trial)

N/A
Recruiting
Research Sponsored by Health Resources and Services Administration (HRSA)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 12 months, and 18 months
Awards & highlights

Summary

This trial will study the effects of three interventions, Mind the Gap, Remaking Recess, and Self Determination Learning Model of Instruction, with and without the addition of an implementation strategy, UNITED.

Who is the study for?
This trial is for families with children aged 2 to 8 diagnosed with Autism Spectrum Disorder (ASD) or Neurodevelopmental Disorders (NDD), who haven't started ASD-specific services outside of school. Participants must speak English, Korean, or Spanish and have a family income below 250% of the federal poverty level. Peer navigators from community organizations serving children with ASD/NDD are also eligible.
What is being tested?
The 'Mind the Gap' intervention is being tested, which involves peer navigators helping parents understand how to access services for their child with ASD/NDD through up to 12 sessions over six months via phone or video conference. The effectiveness of additional implementation strategies will also be evaluated.
What are the potential side effects?
Since this trial focuses on educational and support interventions rather than medical treatments, traditional side effects are not applicable. However, participants may experience varying levels of stress or emotional impact related to navigating care systems.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 12 months, and 18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 12 months, and 18 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Stages of Implementation Completion (SIC)
Secondary study objectives
Caregiver Satisfaction Survey
Change in Coaching Session Data Form from month to month
Family Empowerment Scale (Koren, DeChillo & Friesen, 1992)
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: UNITEDExperimental Treatment1 Intervention
UNITED is premised on the idea that successful implementation in organizations like schools and early intervention systems requires a team-based approach, in which the team is thoughtfully assembled, develops a plan for implementation, assigns roles and responsibilities, and carefully tracks and supports implementation and sustainment in all its stages within a few meetings and ongoing coaching from the research staff.
Group II: Implementation as Usual (IAU)Active Control1 Intervention
The organizations will implement Mind the Gap as usual. The research team will be available to provide support on the Mind the Gap intervention as needed.

Find a Location

Who is running the clinical trial?

University of PennsylvaniaOTHER
2,053 Previous Clinical Trials
43,012,819 Total Patients Enrolled
15 Trials studying Autism Spectrum Disorder
4,259 Patients Enrolled for Autism Spectrum Disorder
Drexel UniversityOTHER
153 Previous Clinical Trials
47,818 Total Patients Enrolled
8 Trials studying Autism Spectrum Disorder
20,751 Patients Enrolled for Autism Spectrum Disorder
University of California, DavisOTHER
928 Previous Clinical Trials
4,720,710 Total Patients Enrolled
14 Trials studying Autism Spectrum Disorder
5,593 Patients Enrolled for Autism Spectrum Disorder

Media Library

Mind the Gap (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT04972825 — N/A
Autism Spectrum Disorder Research Study Groups: UNITED, Implementation as Usual (IAU)
Autism Spectrum Disorder Clinical Trial 2023: Mind the Gap Highlights & Side Effects. Trial Name: NCT04972825 — N/A
Mind the Gap (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04972825 — N/A
Autism Spectrum Disorder Patient Testimony for trial: Trial Name: NCT04972825 — N/A
~64 spots leftby Aug 2025